CFGS
DOVA

Concourse Financial Group Securities’s Dova Pharmaceuticals, Inc. Common Stock DOVA Stock Holding History

Concourse Financial Group Securities’s Portfolio DOVA Stock Details DOVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-250
Closed -$4.05K – 2278
2019
Q2 		$4K Hold
250
– – ﹤0.01% 1850
2019
Q1 		$2K Hold
250
– – ﹤0.01% 2103
2018
Q4 		$1K Buy
+250
New +$4.03K ﹤0.01% 2093

Other funds holding DOVA

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
AAM
Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GKIM
GW&K Investment Management Boston, Massachusetts $11.3B AUM 31.98% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.27% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Concourse Financial Group Securities's DOVA Position: Q3 2019 in Review

Concourse Financial Group Securities sold out of Dova Pharmaceuticals, Inc. Common Stock (DOVA) in Q3 2019, closing a stake of 250 shares — an estimated $4.05K sold.

Concourse Financial Group Securities first reported a position in DOVA in Q4 2018 and held it in 3 quarters. The position peaked at $4K in Q2 2019. 72 funds tracked by Wall St. Rank hold DOVA as of Q3 2019.

  • Concourse Financial Group Securities reported no remaining Dova Pharmaceuticals, Inc. Common Stock position as of Q3 2019 after selling out during the quarter.
  • Concourse Financial Group Securities sold 250 Dova Pharmaceuticals, Inc. Common Stock shares in Q3 2019, an estimated $4.05K.
  • Concourse Financial Group Securities first reported a position in Dova Pharmaceuticals, Inc. Common Stock in Q4 2018 and held it in 3 quarters.
  • Concourse Financial Group Securities's Dova Pharmaceuticals, Inc. Common Stock position peaked at $4K in Q2 2019.
  • 72 funds tracked by Wall St. Rank held Dova Pharmaceuticals, Inc. Common Stock as of Q3 2019.

Based on Concourse Financial Group Securities's 13F filing for Q3 2019, filed 13 Nov 2019.